Rocket Pharmaceuticals received FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1, an inherited immunodeficiency that can be fatal in infancy and early childhood. The approval makes Kresladi the first gene therapy commercial product from Rocket. The report emphasizes that Kresladi is the first approved gene therapy for this ultra-rare immune disorder, underscoring the regulatory pathway for single-therapy approvals in conditions with very limited treatment options. It also signals broader momentum for gene therapy commercialization as regulators continue to expand the gene therapy footprint beyond oncology. For biotech professionals, the approval is immediately actionable—supporting payor and provider readiness planning for manufacturing, delivery, and follow-up care frameworks tied to gene therapy.